TABLE 1.
Features of reported SARS-CoV-2 reinfectionsa
| Authors (reference) | Country | Duration between infections (days or mo) | Initial infection severity (CT value) | Negative intermittent RT-PCR testing (day[s]) | Reinfection severity (CT value) | Genomic feature(s) |
Serology resultsb | |
|---|---|---|---|---|---|---|---|---|
| Infection | Reinfectionc | |||||||
| Tillett et al. (3) | US (NV) | 48 | Mild (35.2) | Yes (38) | Severe (35.3) | Clade 20C | Clade 20C; 7 SNVs compared to reference not seen in initial infection strain | Roche Elecsys anti-SARS-CoV-2 IgM/IgG positive on day 8 of reinfection |
| To et al. (2) | China (Hong Kong) | 142 | Mild (NA) | Yes (20) | Asymptomatic (26.7) | Clade 19A | Clade 20A | Abbott SARS-CoV-2 negative on day 1 of reinfection then positive on day 5 |
| Goldman et al. (8)d | US (WA) | 140 | Severe (26.5) | Yes (39, 40) | Severe (39.6) | Clade 19B | Clade 20A | RBD, spike and NC IgG, spike IgM, spike and NC IgA positive on day 14 of reinfection; nAbs detected on days 14 and 42 of reinfection |
| Gupta et al. (4) | ||||||||
| Case 1 | India | 108 | Asymptomatic (36) | Yes (8) | Asymptomatic (16.6) | NA | 9 SNVs compared to initial infection | NA |
| Case 2 | India | 111 | Asymptomatic (28.2) | Yes (10) | Asymptomatic (16.9) | NA | 10 SNVs compared to initial infection | NA |
| Larson et al. (7) | US (VA) | 64 | Moderate (NA) | NA | Severe (NA) | Partial genome obtainede | Lineage B.1.26; several potential variations and one high-confidence variation compared to initial infection, including D614G | Spike IgG positive on day 8 of reinfection |
| Van Elslande et al. (24) | Belgium | 3 mo | Moderate (25.6) | NA | Mild (32.6) | Lineage B.1.1 | Lineage A | Roche nucleocapsid IgG positive on day 7 of reinfection |
| Prado-Vivar et al. (21)d | Ecuador | 63 | Mild (36.9) | Yes (21) | Moderate (NA) | Clade 20A | Clade 19 B | IgM positive, IgG negative on day 7 of initial infection; IgM and IgG positive on day 28 of reinfection |
| Shastri et al. (22)d | ||||||||
| Case 1 | India | 66 | Mild (32) | Yes (4) | Mild (25) | Lineage B.1 | Lineage B | Abbott anti-NC IgG negative on day 5 of reinfection |
| Case 2 | India | 65 | Asymptomatic (33) | Yes (3) | Mild (36) | Lineage B.1.1 | Lineage B.1.1; 7 SNVs in initial strain compared to reference not present in reinfection strain, including D614G | Abbott NC IgG negative on day 7 of reinfection |
| Case 3 | India | 19 | Asymptomatic (36) | Yes (2) | Mild (21) | Lineage B.1.1 | Lineage B.1.1; 5 SNVs compared to reference not present in initial infection strain, including D614G | NA |
| Case 4 | India | 55 | Mild (32) | NA | Mild (17) | Lineage B.1.1 | Lineage B.1.1; 8 SNVs compared to reference not present in initial infection strain, including D614G | Roche NC total antibody negative on day 20 of reinfection |
| Abu-Raddad et al. (23)d | ||||||||
| Case 1 | Qatar | 46 | Asymptomatic/mild (36) | NA | Asymptomatic/mild (28) | NA | 9 SNVs compared to initial infection strain, including D614G | NA |
| Case 2 | Qatar | 71 | Asymptomatic/mild (17) | NA | Asymptomatic/mild (29) | NA | 11 SNVs compared to initial infection strain, including D614G | NA |
| Case 3 | Qatar | 88 | Asymptomatic/mild (36) | NA | Asymptomatic/mild (25) | NA | Partial genome obtainede; 3 SNVs compared to initial strain, including D614Ge | Roche Elecsys anti-SARS-CoV-2 negative at time of reinfection |
| Case 4 | Qatar | 55 | Asymptomatic/mild (30) | NA | Asymptomatic/mild (32) | Partial genome obtainede | 1 SNV compared to initial infection strain, including D614G | NA |
a
CT, cycle threshold; NA, not available; nAbs, neutralizing antibodies; NC, nucleocapsid; RBD, receptor binding domain; RT-PCR, reverse transcription-PCR; SNV, single nucleotide variant.
b
Serology results reported relative to the day of symptom onset if reported; if not reported or patient asymptomatic, then serology results relative to day of RT-PCR testing.
d
Preprint study.
e
One of the genomes reported was of low quality.